Discover the range of academic oncology titles at Springer Nature here.
Featured Review - ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
In this review, we summarize existing knowledge surrounding the mechanisms of action of ESR1 mutations and roles in resistance to aromatase inhibition. We then analyze the recent literature on how ESR1 mutations affect outcomes in estrogen receptor-targeting and combination therapies.
Aims and scope
Lewis Chodosh, University of Pennsylvania, USA
Trending in the Media
Click here to see the most popular articles published in Breast Cancer Research in the past three months.
Springer Nature Oncology Portfolio
20 years ago Breast Cancer Research published its first articles with BMC. Well-respected in the field, the journal has continually placed in the first quartile of the ‘Oncology’ category of Journal Citation Reports. Over the past decade, Breast Cancer Research (BCR) has also become the highest ranked breast cancer focused title in the field.
Look back at the journal’s milestone achievements and article highlights.
From the blog
COVID-19 and impact on peer review
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Annual Journal Metrics
75 days to first decision for reviewed manuscripts only
38 days to first decision for all manuscripts
153 days from submission to acceptance
20 days from acceptance to publication
5802 Altmetric Mentions